Multi-target-directed ligands to combat neurodegenerative diseases
Our understanding of the pathogenesis of diseases has advanced enormously in recent
decades. As a consequence, drug discovery has gradually shifted from an entirely …
decades. As a consequence, drug discovery has gradually shifted from an entirely …
Privileged scaffolds as MAO inhibitors: Retrospect and prospects
This review aims to be a comprehensive, authoritative, critical, and readable review of
general interest to the medicinal chemistry community because it focuses on the …
general interest to the medicinal chemistry community because it focuses on the …
Emerging therapeutic potentials of dual‐acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases
B Mathew, DGT Parambi, GE Mathew… - Archiv der …, 2019 - Wiley Online Library
No drug has been approved to prevent neuronal cell loss in patients suffering from
Parkinson's disease (PD) or Alzheimer's disease (AD); despite increased comprehension of …
Parkinson's disease (PD) or Alzheimer's disease (AD); despite increased comprehension of …
Multi-target-directed ligands and other therapeutic strategies in the search of a real solution for Alzheimer's disease
A Agis-Torres, M Sollhuber… - Current …, 2014 - ingentaconnect.com
The lack of an adequate therapy for Alzheimer's Disease (AD) contributes greatly to the
continuous growing amount of papers and reviews, reflecting the important efforts made by …
continuous growing amount of papers and reviews, reflecting the important efforts made by …
Past, present and future of A2A adenosine receptor antagonists in the therapy of Parkinson's disease
MT Armentero, A Pinna, S Ferré, JL Lanciego… - Pharmacology & …, 2011 - Elsevier
Several selective antagonists for adenosine A2A receptors (A2AR) are currently under
evaluation in clinical trials (phases I to III) to treat Parkinson's disease, and they will probably …
evaluation in clinical trials (phases I to III) to treat Parkinson's disease, and they will probably …
Therapeutic potential of adenosine A2A receptor antagonists in Parkinson's disease
K Xu, E Bastia, M Schwarzschild - Pharmacology & therapeutics, 2005 - Elsevier
In the pursuit of improved treatments for Parkinson's disease (PD), the adenosine A2A
receptor has emerged as an attractive nondopaminergic target. Based on the compelling …
receptor has emerged as an attractive nondopaminergic target. Based on the compelling …
A convenient one-pot synthesis of 2-substituted benzimidazoles
R Trivedi, SK De, RA Gibbs - Journal of Molecular Catalysis A: Chemical, 2006 - Elsevier
A convenient one-pot synthesis of 2-substituted benzimidazoles - ScienceDirect Skip to main
contentSkip to article Elsevier logo Journals & Books Search RegisterSign in View PDF Download …
contentSkip to article Elsevier logo Journals & Books Search RegisterSign in View PDF Download …
[图书][B] Strategies for organic drug synthesis and design
D Lednicer - 2009 - books.google.com
This book examines and evaluates the strategies utilized to design and synthesize
pharmaceutically active agents. Significant updates over the last 10 years since the …
pharmaceutically active agents. Significant updates over the last 10 years since the …
Xanthines as adenosine receptor antagonists
The natural plant alkaloids caffeine and theophylline were the first adenosine receptor (AR)
antagonists described in the literature. They exhibit micromolar affinities and are non …
antagonists described in the literature. They exhibit micromolar affinities and are non …
Synthesis, reactivity and biological activity of benzimidazoles
Benzimidazole is a biologically important scaffold which displays important biological
activities. Recent progress in the synthesis and bioactivity of benzimidazoles is reviewed …
activities. Recent progress in the synthesis and bioactivity of benzimidazoles is reviewed …